WS #7976

The dominant signal in this window is the resignation of Tulsi Gabbard as Director of National Intelligence, effective June 30, citing her husband's cancer diagnosis. This is confirmed by multiple major outlets (BBC, NBC, CNN, Fox, Reuters, NYT, Axios, Bloomberg) and is the fourth cabinet departure. While the stated reason is personal, reports note she clashed with hawkish Trump officials on Iran policy, and Trump has named Aaron Lukas as acting DNI. The resignation itself is unlikely to move markets directly, but it adds to administration instability and may signal internal divisions on Iran strategy. Separately, Iran's foreign ministry spokesperson made multiple statements indicating negotiations are not close, differences are deep, and the focus is on ending the war—not on nuclear details. This reinforces the prevailing bearish oil thesis (Strait of Hormuz disruption, elevated crude). USTR Greer stated no immediate semiconductor tariffs, which is a modest positive for chip stocks (NVDA, AMD, QCOM, MU). The FDA approved the first treatment for chronic hepatitis delta virus (Hepcludex), a positive for Gilead (GILD) and other liver-focused biotechs. Novo Nordisk received a positive CHMP opinion for Wegovy 7.2 mg in the EU, supporting NVO. Marvell Technology (MRVL) is up 2.7% on analyst upgrades ahead of May 27 earnings, driven by custom AI silicon. Uber is evaluating a full acquisition of Delivery Hero, which could face regulatory hurdles. The SEC delayed prediction market ETFs from Roundhill, GraniteShares, and Bitwise, a negative for crypto-related ETFs. Overall, the macro narrative is stable: oil elevated, Iran talks not progressing, tech stocks mixed (NVDA weak, MRVL strong), and political noise from Gabbard's resignation is unlikely to be a sustained market driver.